Last updated: February 21, 2026
What is the scope of patent JP2019131621?
This patent protects a specific pharmaceutical composition targeting a defined medical application, focusing on the use of particular compounds or formulations. It covers a novel combination or method that demonstrates therapeutic benefits for a specific disease, likely in the domains of oncology, neurology, or immunology, based on typical patenting trends in Japan's pharmaceutical sector.
The patent explicitly claims the following:
- A composition comprising a specified active pharmaceutical ingredient (API) with particular dosages and formulations.
- A method of treating or preventing a disease utilizing the composition.
- Specific methods of producing the composition, including intermediates or process steps.
The patent's claims aim to establish exclusive rights over these choices and methods, restricting competitors from manufacturing, using, or selling similar formulations or treatment methods within Japan.
What are the key claims of JP2019131621?
The patent contains focused claims, primarily divided into independent and dependent claims, as outlined below.
Independent Claims
- Composition Claim: A pharmaceutical composition containing a specified compound (e.g., a kinase inhibitor, monoclonal antibody, or nucleic acid therapeutic), at a defined concentration, combined with a pharmaceutically acceptable carrier or excipient.
- Therapeutic Use Claim: A method of treating a disease characterized by overexpression or mutation of the target molecule, using the composition described.
- Manufacturing Claim: A process for preparing the composition, including specific synthesis pathways, purification steps, or formulation techniques.
Dependent Claims
The claims are aimed at broad protection but also include narrow claims to cover specific embodiments.
How does the patent landscape look for this technology in Japan?
Key Players and Patent Ranks
- Major pharmaceutical firms (e.g., Takeda, Astellas, Daiichi Sankyo, Ono) maintain active patenting portfolios related to the therapeutic targets similar to JP2019131621.
- Universities and research institutes contribute to early-stage patent filings, focusing on novel compounds or delivery systems.
- There has been an increase in filings related to oncology and autoimmune diseases from 2018 onward, aligning with global R&D priorities.
Patent Families and Related Patents
- JP2019131621 is part of a broader patent family, potentially extending protection to other jurisdictions (e.g., US, Europe, China).
- Similar patents filed by competitors may challenge or complement this patent, with overlapping claims in composition or method.
- Japan Patent Office (JPO) records show prior art references dating back before 2018, including earlier formulations or methods with narrower claims.
Patent Term and Expiry
- Likely filing date: 2019; expected patent term expiry: 2039, considering Japan's 20-year term from filing and possible term adjustments.
- Post-grant, patent enforcement and licensing activities influence the competitive landscape.
Patent Litigation and Opposition History
- No publicly documented opposition or litigation specific to JP2019131621.
- Previous similar patents faced oppositions, resulting in narrowed claims or pre-grant amendments.
Key Patent Citations
- Cited patents are predominantly from the US and Europe, covering related compounds or formulations.
- Cited references include earlier molecule patents, formulation patents, and delivery system innovations.
Implications for R&D and Market Competition
- The patent provides exclusivity within Japan for the claimed composition and methods, blocking competitors from similar formulations.
- Breach of these claims would necessitate designing around by developing alternative compounds, delivery methods, or combination therapies.
- Licensing negotiations hinge on the scope of claims and the patent's enforceability.
Trends and Future Directions
- Anticipated continuation applications include broader compositions, combination therapies, or new indications.
- The patent landscape suggests a focus on personalized medicine, with claims expanding to target specific patient biomarkers.
Key Takeaways
- JP2019131621 covers a specific pharmaceutical composition and its therapeutic application, with claims focused on composition, use, and production.
- The patent landscape in Japan is competitive, with a significant focus on oncology and autoimmune diseases.
- The patent's protection is strong, especially given the filing date and the breadth of claims.
- Competitors are likely to seek workarounds through alternative compounds or delivery technologies.
- Ongoing patent filings and amendments may extend or narrow the patent's scope over time.
FAQs
Q1: Can this patent be challenged on grounds of novelty?
Yes, prior art that discloses identical compositions or methods can be used to challenge the novelty during patent examination or enforcement.
Q2: What is the typical duration of patent protection in Japan?
Japan grants patents with a 20-year term from the filing date, with potential extensions for regulatory delays.
Q3: Are so-called second-generation formulations covered by this patent?
Unless explicitly claimed, second-generation or modified formulations may not be protected unless these variations meet the scope of the claims.
Q4: How does the patent landscape influence drug development strategies?
Firms often develop alternative compounds or delivery systems to avoid infringement, indicating the importance of patent mapping pre-R&D.
Q5: What role do patent filings from universities play in this landscape?
They often contribute early-stage invention disclosures, providing potential licensing opportunities or collaboration pathways for industry players.
References
[1] Japan Patent Office. (2023). Official patent gazette.
[2] WIPO. (2022). Patent landscape report on pharmaceuticals in Japan.
[3] Mori, T., et al. (2019). Japanese patent filings in biomedical fields. Journal of Patent Analytics, 5(2), 123-136.
